Answering Pivotal Questions in the Diagnosis and Treatment of Primary Biliary Cirrhosis and Non-Alcoholic Steatohepatitis

Chairperson:

Michael Trauner¹

Speakers:

David E.J. Jones,² Vlad Ratziu³

1. Medical University of Vienna, Vienna, Austria
2. Newcastle University, Newcastle upon Tyne, UK
3. Hôspital Pitié-Salpêtrière Université Pierre et Marie Curie, Paris, France

Disclosure:

Michael Trauner has consulted for AbbVie, Albireo Pharma, Falk Pharma, Gilead, Intercept Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and Phenex Pharmaceuticals; and has received speaker honoraria from Falk Pharma, Genfit, and Merck Sharp & Dohme Corp. David E.J. Jones has consulted for GSK, Pfizer, and Intercept Pharmaceuticals; has received research funding (to UK-PBC) from Intercept Pharmaceuticals, GSK, and Lumena; and has received speaker honoraria from Falk Pharma. Vlad Ratziu has consulted for Intercept Pharmaceuticals, Genfit, Tobira, and Galmed.

Acknowledgements:

Writing assistance was provided by Dr Ewen Legg of Halcyon Medical Writing.

Support:

Medical writing assistance was funded by Intercept Pharmaceuticals, Inc. The views and opinions expressed are those of the authors as stated during the symposium and are not necessarily those of Intercept Pharmaceuticals, Inc.

Citation:

EMJ Hepatol. 2015;3[2]:52-59. DOI/10.33590/emjhepatol/10311344. https://doi.org/10.33590/emjhepatol/10311344.

Keywords:

Cirrhosis, Non Alcoholic SteatoHepatitis, International Liver Congress, Hepatology

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.